REFERENCES
- Kalso E. Oxycodone. J Pain Symptom Manage. 2005;29:S47–56.
- Pöyhiä R, Seppälä T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33:617–21.
- Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther. 1992b;52:487–95.
- Koizumi W, Toma H, Watanabe K, Katayama K, Kawahara M, Matsui K, Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting 5 mg tablets. Jpn J Clin Oncol. 2004;34:608–14.
- Narabayashi M, Saijo Y, Takenoshita S, Chida M, Shimoyama N, Miura T, Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: An open-label trial. Jpn J Clin Oncol. 2008;38:296–304.
- Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth. Analg. 1995;80:296–302.
- Villesen HH, Banning AM, Petersen RH, Weinelt S, Poulsen JB, Hansen SH, Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. Therapeutics Clin Risk Manage. 2007;3:961–7.
- Kokubun H, Fukawa M, Matoba M, Hoka S, Yamada Y, Yago K. Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. Biol Pharm Bull. 2007;30:2173–7.
- Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology. 2009;110:1371–8.
- Saari TI, Grönlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol. 2010;66:387–97.
- Beal SL, Sheiner LB, (eds.), NONMEM Users Guides, NONMEM Project Group, San Francisco, University of California at San Francisco, 1992.
- DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41
- Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Cappareli EV. Model appropriateness and population pharmacokinetics modeling. J Clin Pharmacol. 2003;43:610–23.
- Wings for NONMEM, Holford N.G. Available at http://wfn.sourceforge.net./ Accessed Jun 12, 2012
- Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol. 2009;65: 263–71.
- Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol. 2010;66:977–85.
- Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krahenbuhl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol. 2011;67:63–71.
- Charles B, Hardy J, Anderson H, Tapuni A, George R, Norris R. Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? Support Care Cancer. 2014;22:325–30.
- Komatsu T, Kokubun H, Suzuki A, Takayanagi R, Yamada Y, Matoba M, Population pharmacokinetics of oxycodone in patients with cancer-related pain. J Pain Palliat Care Pharmacother. 2012;26:220–5.
- Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther. 1996;59:52–61.
- Cherrier MM, Amory JK, Ersek M, Risler L, Shen DD. Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults. J Pain. 2009;10:1038–50.
- Saari TI, Ihmsen H, Neuvonen PJ, Olkkola KT, Schwilden H. Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth. 2012;108:491–8.
- Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther. 2008;84:462–7.